Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 21, 2020 11:47 ET | Source: Moore Kuehn

Moore Kuehn Encourages MYOK, BSTC, CIT, and PE and Investors to Contact Law Firm

NEW YORK, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether...
October 19, 2020 15:14 ET | Source: Rigrodsky & Long, P.A.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of MYOK, CBMG, CIT, and STND Mergers

WILMINGTON, Del., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: MyoKardia, Inc. (NASDAQ GS: MYOK) regarding possible breaches of fiduciary...
October 05, 2020 21:00 ET | Source: Rigrodsky & Long, P.A.

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of MyoKardia, Inc. Buyout

WILMINGTON, Del., Oct. 05, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating MyoKardia, Inc. (“MyoKardia”) (NASDAQ GS: MYOK) regarding possible breaches of...
October 05, 2020 14:57 ET | Source: Bragar Eagel & Squire

MYOKARDIA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of MYOK and Encourages Investors to Contact the Firm

NEW YORK, Oct. 05, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of...
August 26, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Announces Abstracts Selected for Presentation at the European Society of Cardiology Congress 2019

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the presentation of three abstracts at the upcoming European Society of Cardiology (ESC)...
June 24, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive...
January 23, 2019 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Appoints William Fairey as Chief Commercial Officer

SOUTH SAN FRANCISCO, Calif., Jan. 23, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
June 26, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Doses First Patient in Pivotal Phase 3 EXPLORER-HCM Trial of Mavacamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., June 26, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
May 21, 2018 07:30 ET | Source: MyoKardia, Inc.

MyoKardia Announces Design of Phase 3 EXPLORER-HCM Study Evaluating Mavacamten in Symptomatic, Obstructive Hypertrophic Cardiomyopathy

Single Pivotal to Support Registration; Target Enrollment of 220 Patients; Primary Endpoint of Clinical Response Using Peak VO2 and NYHA Classification Improvements Expected to Initiate in Second...
May 10, 2018 08:30 ET | Source: MyoKardia, Inc.

MyoKardia Doses First Patient in PIONEER Open-Label Extension Study of Mavacamten for Symptomatic, Obstructive Hypertrophic Cardiomyopathy

SOUTH SAN FRANCISCO, Calif., May 10, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...

Next Page keyboard_arrow_right